ONCOSIL® -250


TERBINAFINE 250MG TABLETS

Product Enquiry
Category:

Description

TERBINAFINE 250MG TABLETS

  • In onychomycoses, Griseofuvin has done its part for so many years but relapse rates, high incidence of liver toxicity and limited spectrum of antifungal activity make terbinafine, Oncosil, the preferred treatment of choice. A continuous administration regimen of 250 mg, 6 weeks for fingernail and 12 weeks for toenail onychomycosis has a 76% mycological and clinical cure rate higher than itraconazole.
  • According to a meta-analysis by Gupta and Foley et al (2015), Oncosil 1% cream is considered first line in treatment of Pityariasis versicolor on a twice daily dosing with a 90% mycological cure rate on day 14 and 100% complete cure rate on the 28th day. Topical Oncosil, for Pityriasis versicolor can be administered with the first line systemic antifungal, itraconazole (Itranox) 200 mg for 7 days to boost cure rates and treat stubborn tinea versicolor with a mycological cure of 90% (Kose et al, 2002) and a complete cure rate of 87% (Galimberti et al, 1987).
  • In tinea corporis and pedis, a period of 4 weeks of 250 mg/day PO in single dose or divided every 12 hours will achieve cure rates and Oncosil is first line.”